Keyphrases
Lung Cancer
100%
Personalized Treatment
100%
Targeted Therapy
100%
Epidermal Growth Factor Receptor
50%
Early Tumor
50%
Tarceva
50%
MET Inhibitor
33%
Tumor Cells
33%
Targeted Inhibitors
33%
Inhibitor Drug
33%
Receptor-interacting Protein Kinase 1 (RIPK1)
16%
Genetic Changes
16%
Inhibitor Treatment
16%
Lethal Cancer
16%
Erlotinib
16%
Long-term Clinical Outcome
16%
Human Cancer
16%
Resistance Mechanisms
16%
Targeted Therapeutics
16%
North America
16%
Cancer-associated Proteins
16%
T790M
16%
Bioluminescence
16%
Achilles Heel
16%
State-of-the-art Research
16%
Lung Tumor
16%
Current Therapies
16%
Drug-resistant Tumor
16%
Clinical Survival
16%
Patient Demographics
16%
Prognostic Factors
16%
PHA665752
16%
Patient Response
16%
Molecular Factors
16%
Clinical Trials
16%
Small Animal
16%
Molecular Determinants
16%
Cancer-related
16%
Lung Cancer Treatment
16%
PET-MRI
16%
Survivors
16%
Response Predictors
16%
MET Receptor
16%
Signaling Pathway
16%
Cancer Mechanisms
16%
Molecular Targets
16%
Tumor Xenograft
16%
Most Vulnerable
16%
Metastatic Lung Cancer
16%
Immunohistochemical Analysis
16%
Cancer Genetics
16%
Lung Cancer Patients
16%
High Mortality Rate
16%
Novel Therapeutics
16%
Response Mechanism
16%
Predictive Factors
16%
Cell Fate
16%
Recurrent Disease
16%
Disease Targets
16%
Residual Disease
16%
Annual Incidence
16%
Multiplexed Imaging
16%
Treatment Pressure
16%
Combinatorial Regimens
16%
Target Discovery
16%
Resistant mutation
16%
SU11274
16%
Medicine and Dentistry
Targeted Therapy
100%
Lung Cancer
100%
Erlotinib
44%
Malignant Neoplasm
44%
Epidermal Growth Factor Receptor
33%
Neoplasm
33%
Tumor Cell
22%
Receptor Protein
11%
Positron Emission Tomography - Magnetic Resonance Imaging
11%
5 (2,6 Dichlorobenzylsulfonyl) 3 [3,5 Dimethyl 4 [2 (1 Pyrrolidinylmethyl) 1 Pyrrolidinylcarbonyl] 1h Pyrrol 2 Ylmethylene] 1,3 Dihydro 2h Indol 2 One
11%
Patient Population
11%
Scatter Factor Receptor
11%
Recurrent Disease
11%
Cancer Genetics
11%
Tumor Xenograft
11%
Cell Signaling Pathway
11%
Clinical Trial
11%
Minimal Residual Disease
11%
Lung Tumor
11%
Cancer Therapy
11%
Gene Mutation
11%
Molecular Imaging
11%
Prognostic Factor
11%
Mortality Rate
11%
Cell Fate
11%
Bioluminescence
11%
N (3 Chlorophenyl) 3 [3,5 Dimethyl 4 (4 Methyl 1 Piperazinylcarbonyl) 1h Pyrrol 2 Ylmethylene] 2,3 Dihydro N Methyl 2 Oxo 1h Indole 5 Sulfonamide
11%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Neoplasm
55%
Erlotinib
44%
Malignant Neoplasm
44%
Epidermal Growth Factor Receptor
33%
Cabozantinib
22%
Scatter Factor Receptor
11%
Recurrent Disease
11%
Clinical Trial
11%
Lung Tumor
11%
Mortality Rate
11%
N (3 Chlorophenyl) 3 [3,5 Dimethyl 4 (4 Methyl 1 Piperazinylcarbonyl) 1h Pyrrol 2 Ylmethylene] 2,3 Dihydro N Methyl 2 Oxo 1h Indole 5 Sulfonamide
11%
5 (2,6 Dichlorobenzylsulfonyl) 3 [3,5 Dimethyl 4 [2 (1 Pyrrolidinylmethyl) 1 Pyrrolidinylcarbonyl] 1h Pyrrol 2 Ylmethylene] 1,3 Dihydro 2h Indol 2 One
11%
Minimal Residual Disease
11%
Receptor Protein
11%